Cargando…

ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms

Type II topoisomerases (TOP2) poisons represent one class of the most successful and widely prescribed chemotherapeutics, which is frontline therapy for a myriad of systemic cancers and solid tumors, including lymphomas, leukemias, and lung cancer. Despite this, treatment with this class of drugs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Jianfeng, Wang, Xiaofang, Yang, Xuejie, Zhao, Guofang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845372/ https://www.ncbi.nlm.nih.gov/pubmed/36650267 http://dx.doi.org/10.1038/s41598-023-28185-z

Ejemplares similares

Author Correction: ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms
por: Shu, Jianfeng, et al.
Publicado: (2023)

Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
por: ZHU, YING, et al.
Publicado: (2014)

Evaluation of ATM Kinase Inhibitor KU-55933 as Potential Anti-Toxoplasma gondii Agent
por: Munera López, Jonathan, et al.
Publicado: (2019)

Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
por: Barker, Catherine R., et al.
Publicado: (2006)

Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin
por: Zakikhani, Mahvash, et al.
Publicado: (2012)

The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison
por: Cowell, Ian G., et al.
Publicado: (2019)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
por: Hawtin, Rachael E., et al.
Publicado: (2010)

Prognostic Values of Filamin-A Status for Topoisomerase II Poison Chemotherapy
por: Yue, Jingyin, et al.
Publicado: (2012)

Etoposide Quinone Is a Covalent Poison of Human Topoisomerase IIβ
por: Smith, Nicholas A., et al.
Publicado: (2014)

Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy
por: Mehta, Amol, et al.
Publicado: (2018)

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
por: Marinello, Jessica, et al.
Publicado: (2018)

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells
por: More, Piyush, et al.
Publicado: (2019)

Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency
por: Álvarez-Quilón, Alejandro, et al.
Publicado: (2020)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Downregulated Ku70 and ATM associated to poor prognosis in colorectal cancer among Chinese patients
por: Lu, Yuanfang, et al.
Publicado: (2014)

The Ku complex promotes DNA end-bridging and this function is antagonized by Tel1/ATM kinase
por: Rinaldi, Carlo, et al.
Publicado: (2023)

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents
por: Blower, Tim R, et al.
Publicado: (2019)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Signal-induced enhancer activation requires Ku70 to read topoisomerase1–DNA covalent complexes
por: Tan, Yuliang, et al.
Publicado: (2023)

The ATP-dependent chromatin remodelling enzyme Uls1 prevents Topoisomerase II poisoning
por: Swanston, Amy, et al.
Publicado: (2019)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons
por: Gokare, Prashanth, et al.
Publicado: (2016)

ATM Deficiency Results in Accumulation of DNA-Topoisomerase I Covalent Intermediates in Neural Cells
por: Alagoz, Meryem, et al.
Publicado: (2013)

Molecular mechanism of topoisomerase poisoning by the peptide antibiotic albicidin
por: Michalczyk, Elizabeth, et al.
Publicado: (2023)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase
por: Sharma, Abhishek Bharadwaj, et al.
Publicado: (2021)

Synergistic antibacterial activity of carvacrol loaded chitosan nanoparticles with Topoisomerase inhibitors and genotoxicity evaluation
por: Akhlaq, Amina, et al.
Publicado: (2023)

Mitotic chromosomes are constrained by topoisomerase II–sensitive DNA entanglements
por: Kawamura, Ryo, et al.
Publicado: (2010)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
por: Barthelmes, H U, et al.
Publicado: (2001)

Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons
por: Zdraljevic, Stefan, et al.
Publicado: (2017)

Tuning the surface coating of IONs toward efficient sonochemical tethering and sustained liberation of topoisomerase II poisons
por: Michalkova, Hana, et al.
Publicado: (2019)

Lack of Ku80 Alteration in Multiple Myeloma
por: Kato, Miyuki, et al.
Publicado: (2002)

Chfr and RNF8 synergistically regulate ATM activation
por: Wu, Jiaxue, et al.
Publicado: (2011)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a82r2pbh0h0s3nsn0ehudoosmg